34 results
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
16 Apr 24
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
4:20pm
manufacturing activity, and lower personnel costs due to fewer research and development headcount compared to prior year.
Administrative expenses … December 31,
(in USD thousands)
Research and development expenses
Administrative expenses
Net impairment losses
Other income
Other (losses)/gains - net
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
.
1.18. “Develop” or “Development” shall mean to conduct any non-clinical or clinical drug research or development activities, whether before or after
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
as of December 31, 2022. The decrease was mainly due to ongoing research and development (R&D) costs associated with the Company’s clinical drug programs … )
Research and development expenses
Administrative expenses
Other income
Other gains - net
Operating loss
Finance income
Finance cost
Finance income - net
Net
6-K
CNTB
Connect Biopharma Holdings Ltd
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
Statements of Loss
For Six Months Ended June 30,
Notes
RMB’000
USD’000
Note 2
Research and development expenses
Administrative expenses
Other … in the interim condensed consolidated statements of loss:
Six Months Ended June 30,
RMB’000
Research and development expenses
Administrative expenses
7.Other
6-K
EX-99.1
im28vncgev 2cbemy9
5 Jun 23
Current report (foreign)
4:28pm
6-K
EX-99.1
9515zc
11 Apr 23
Connect Biopharma Reports Full Year 2022 Financial Results
5:00pm
6-K
ynj92o7djx2 9m
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
6-K
EX-99.1
bli84fsf 7v8lk
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
F-3/A
pua1i2d
17 Jun 22
Shelf registration (foreign) (amended)
5:19pm
6-K
EX-99.1
6cibstwkdnc
10 Jun 22
Current report (foreign)
6:05am
F-3/A
efy7mz
20 May 22
Shelf registration (foreign) (amended)
6:54pm
F-3
pg3w4he
15 Apr 22
Shelf registration (foreign)
5:27pm
6-K
EX-99.1
b25cs4e6 99pftxav
31 Mar 22
Connect Biopharma Reports Full Year 2021 Financial Results
5:15pm
20-F
EX-4.12
yoqc2i42 mf
31 Mar 22
Annual report (foreign)
4:33pm
20-F
mggfy vg0ec
31 Mar 22
Annual report (foreign)
4:33pm
6-K
bej5ht
1 Mar 22
Current report (foreign)
4:16pm
6-K
EX-99.1
entcudubf2hvy3jop
16 Feb 22
Current report (foreign)
4:01pm
6-K
EX-99.1
zfs3v
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm